Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Antifibrotic Therapy for f-ILD
NCT07141810Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 4, randomised, open-label trial of nintedanib and pirfenidone in fibrotic interstitial lung disease (ILD) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Forced Vital Capacity percent predicted at 48 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
nintedanibpirfenidone
03
Conditions
fibrotic interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07141810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141810.